These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 37165825)

  • 21. Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long-term outcome.
    Tektonidou MG; Sotsiou F; Nakopoulou L; Vlachoyiannopoulos PG; Moutsopoulos HM
    Arthritis Rheum; 2004 Aug; 50(8):2569-79. PubMed ID: 15334471
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Diagnostic Value of New Additional Antiphospholipid Antibodies in Antiphospholipid Syndrome.
    Khogeer H; Altahan S; Alrehaily A; Sheikh A; Awartani K; Al-Kaff M; Saleh S; Alzahrani H; Alfattani A; Owaidah T
    Ann Clin Lab Sci; 2021 Jul; 51(4):552-556. PubMed ID: 34452895
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identifying high-risk profile in primary antiphospholipid syndrome through cluster analysis: French multicentric cohort study.
    Guedon AF; Ricard L; Laurent C; De Moreuil C; Urbanski G; Deriaz S; Gerotziafas G; Elalamy I; Audemard A; Chasset F; Alamowitch S; Sellam J; Boffa JJ; Cohen A; Wahl C; Abisror N; Maillot F; Fain O; Mekinian A
    RMD Open; 2023 Mar; 9(1):. PubMed ID: 36894193
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Progress in the field of animal models of antiphospholipid syndrome.
    Gao X; Ma D; Mi L; Zhao J; An Q; Guo Z; Yang B; Zhang L; Xu K
    Autoimmunity; 2024 Dec; 57(1):2391350. PubMed ID: 39155523
    [TBL] [Abstract][Full Text] [Related]  

  • 25. How to Identify High-Risk APS Patients: Clinical Utility and Predictive Values of Validated Scores.
    Oku K; Amengual O; Yasuda S; Atsumi T
    Curr Rheumatol Rep; 2017 Aug; 19(8):51. PubMed ID: 28741233
    [TBL] [Abstract][Full Text] [Related]  

  • 26. What have we learned about antiphospholipid syndrome from patients and antiphospholipid carrier cohorts?
    Pengo V; Banzato A; Bison E; Bracco A; Denas G; Ruffatti A
    Semin Thromb Hemost; 2012 Jun; 38(4):322-7. PubMed ID: 22399307
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antibodies to phosphatidylserine/prothrombin (aPS/PT) enhanced the diagnostic performance in Chinese patients with antiphospholipid syndrome.
    Zhang S; Wu Z; Zhang W; Zhao J; Norman GL; Zeng X; Zhang F; Li Y
    Clin Chem Lab Med; 2018 May; 56(6):939-946. PubMed ID: 29561729
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Venous thromboembolism and antiphospholipid syndrome - considerations on diagnosis and treatment].
    van Mens TE; Middeldorp S; Coppens M
    Ned Tijdschr Geneeskd; 2023 Mar; 167():. PubMed ID: 36928879
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical characteristics and thrombosis outcomes of paediatric antiphospholipid syndrome: analysis of 58 patients.
    Ma J; Song H; Wei M; He Y
    Clin Rheumatol; 2018 May; 37(5):1295-1303. PubMed ID: 28748509
    [TBL] [Abstract][Full Text] [Related]  

  • 30. First-Line, Non-Criterial Antiphospholipid Antibody Testing for the Diagnosis of Antiphospholipid Syndrome in Clinical Practice: A Combination of Anti-β
    Nakamura H; Oku K; Amengual O; Ohmura K; Fujieda Y; Kato M; Bohgaki T; Yasuda S; Atsumi T
    Arthritis Care Res (Hoboken); 2018 Apr; 70(4):627-634. PubMed ID: 28686816
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical and prognostic significance of antinuclear antibodies in primary antiphospholipid syndrome: A multicenter retrospective study.
    Ricard L; Laurent C; Papo M; Deriaz S; Catano J; Alamowitch S; Kayem G; Chasset F; De Moreuil C; Boffa JJ; Gerotziafas G; Elalamy I; Bornes M; Maillot F; Audemard-Verger A; Planche V; Ballot E; Fain O; Mekinian A
    Joint Bone Spine; 2022 Mar; 89(2):105297. PubMed ID: 34656751
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk Factors for the Development of the Disease in Antiphospholipid Antibodies Carriers: A Long-term Follow-up Study.
    Pablo RD; Cacho PM; López-Hoyos M; Calvo-Río V; Riancho-Zarrabeitia L; Martínez-Taboada VM
    Clin Rev Allergy Immunol; 2022 Apr; 62(2):354-362. PubMed ID: 34216367
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differences in Antiphospholipid Antibody Profile between Patients with Obstetric and Thrombotic Antiphospholipid Syndrome.
    Anunciación-Llunell A; Muñoz C; Roggenbuck D; Frasca S; Pardos-Gea J; Esteve-Valverde E; Alijotas-Reig J; Miró-Mur F
    Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361608
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical characterization of antiphospholipid syndrome by detection of IgG antibodies against β2 -glycoprotein i domain 1 and domain 4/5: ratio of anti-domain 1 to anti-domain 4/5 as a useful new biomarker for antiphospholipid syndrome.
    Andreoli L; Chighizola CB; Nalli C; Gerosa M; Borghi MO; Pregnolato F; Grossi C; Zanola A; Allegri F; Norman GL; Mahler M; Meroni PL; Tincani A
    Arthritis Rheumatol; 2015 May; 67(8):2196-204. PubMed ID: 25939498
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Annexin-A5 resistance and non-criteria antibodies for the diagnosis of seronegative antiphospholipid syndrome.
    Ferreira TG; Delhommeau F; Johanet C; Gerotziafas G; Bornes M; Cohen J; Kayem G; Fain O; Planche V; Mékinian A
    Clin Rheumatol; 2020 Apr; 39(4):1167-1171. PubMed ID: 31925628
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk factors for arterial thrombosis in antiphospholipid syndrome.
    Matyja-Bednarczyk A; Swadźba J; Iwaniec T; Sanak M; Dziedzina S; Ćmiel A; Musiał J
    Thromb Res; 2014 Feb; 133(2):173-6. PubMed ID: 24321419
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Added value of non-criteria antiphospholipid antibodies for antiphospholipid syndrome: lessons learned from year-long routine measurements.
    Žigon P; Podovšovnik A; Ambrožič A; Tomšič M; Hočevar A; Gašperšič N; Rotar Ž; Praprotnik S; Šemrl SS; Čučnik S
    Clin Rheumatol; 2019 Feb; 38(2):371-378. PubMed ID: 30099654
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prothrombotic mechanisms based on the impairment of fibrinolysis in the antiphospholipid syndrome.
    Forastiero R; Martinuzzo M
    Lupus; 2008 Oct; 17(10):872-7. PubMed ID: 18827051
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Thrombotic risk in the antiphospholipid syndrome.
    Lim W
    Semin Thromb Hemost; 2014 Oct; 40(7):741-6. PubMed ID: 25299926
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epigenetics-mediated pathological alternations and their potential in antiphospholipid syndrome diagnosis and therapy.
    Tan Y; Liu Q; Li Z; Yang S; Cui L
    Autoimmun Rev; 2022 Aug; 21(8):103130. PubMed ID: 35690246
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.